Skip to main content

Palmitic acid promotes cancer metastasis and leaves a more aggressive “memory” in tumour cells

10 Nov 21




Press & Communications Section Head
Tel.+34 93 40 37255

Researchers at IRB Barcelona publish in the journal Nature the mechanism by which dietary palmitic acid (and not oleic or linoleic acid) favours tumour expansion.

Tumour cells temporarily exposed to a diet rich in palmitic acid develop a more aggressive profile that endures as a form of cellular “memory”.

This more aggressive profile drives the activation Schwann cells associated with the tumor and the secretion of an extracellular tissue which, when blocked, impedes the metastatic capacity of the tumour.


Ninety per cent of cancer deaths are caused by metastasis, that is to say, the spread of the primary tumour to other organs. Scientists led by ICREA researcher Dr. Salvador Aznar-Benitah at IRB Barcelona have described the mechanism by which a diet rich in palmitic acid makes tumour cells more aggressive, conferring them a greater capacity to metastasize.

The authors have identified several “memory” markers left in tumour cells after exposure to palmitic acid: a change that causes cells to conserve greater metastatic capacity, even months after exposure to the fatty acid and that it could be related to a greater capacity of these tumor cells to promote innervation.

“In 2017, we published a study indicating that palmitic acid correlates with increased risk of metastasis, but we didn’t know the mechanism responsible for this. In this study, we detail the process and reveal the involvement of a metastatic capacity “memory” factor and we point to a therapeutic approach to reverse it. This is promising,” says Dr. Aznar-Benitah.

The metastatic “memory” of palmitic acid

In this work, oral tumour cells and melanomas from patients were exposed to a diet rich in palmitic acid. When transplanted into mice, it was observed that they showed a greater capacity to metastasize, even when this diet was administered for a short period prior to the transfer.  The alterations of the genome (known as epigenetic modifications) of metastatic cells caused by the fatty acid are permanent and, consequently, the cells maintain the most “aggressive” properties in a stable manner. The authors describe this behaviour as a “stable memory”.

Our results indicate that a diet rich in palm oil would favour the development of cancer, even if exposure to this fatty acid occurs in a very early stage of the disease in which the primary tumour may still not have been detected. The scientists have observed that this expansive and colonising capacity is acquired as a result of the consumption of palmitic acid (predominant in palm oil), but not of oleic acid (abundant in olive oil) or linoleic acid (characteristic of flaxseed). These results suggest that aggressiveness is linked not only to fat metabolism but also to epigenetic modifications that occur in tumour cells in response to exposure to palmitic acid.

Tumour innervation: key to its spread

For a tumour cell to metastasize, first it must detach from the tumour of origin, enter the bloodstream or lymphatic system, reach another organ, and survive and grow there. In this study, the authors have identified that a diet rich in palmitic acid allows tumour cells to form a neural network around the tumour.

The tumour cells with the most metastatic capacity (i.e. with memory) get the capacity to attract the nervous system, and the neural network that forms around the tumour produces a regenerative environment, which the cells use to their advantage to grow and spread.

Slowing down metastasis by blocking Schwann cells

One of the key elements in the formation of the neural network that favours metastasis are the so-called Schwann cells, which surround and protect neurons. The study published in the journal Nature demonstrates that various approaches to block Schwann cells inhibit the development of this neural network, thereby preventing metastasis.

“This discovery paves the way for research into and the development of therapies that specifically block cancer metastasis, a process that is almost always the cause of death by cancer,” concludes Dr. Gloria Pascual, associate researcher in the Stem Cells and Cancer lab at IRB Barcelona and co-first author of the paper together with Dr. Diana Domínguez.


This work has been carried out using the latest single-cell RNA sequencing and positional RNA sequencing technologies, which have allowed detailed characterisation of the composition of the distinct cells that form the tumour. This is one of the first times that positional RNA-sequencing technology has been used to study the cell composition of metastases.

The study involved the collaboration of the group headed by Dr. Ali Shilatifard (Feinberg School of Medicine - Northwestern University), who co-led the work. The labs of Dr. Holger Heyn (CNAG-CRG), Dr. Ramin Shiekhattar (Silvester Cancer Center, University of Miami), Dr. Coro Bescós (Hospital Vall d’Hebrón) and Dr. Neus Prats (Histopathology Unit, IRB Barcelona) also participated in the study.

The study has been funded by Worldwide Cancer Research, the Asociación Española Contra el Cáncer, the Marató de TV3, the BBVA Foundation, the European Research Council, the Government of Catalonia, the Ministry of Science and Innovation of the Government of Spain, the Lilliane Bettencourt Foundation, “la Caixa” Foundation, the National Cancer Institute and the University of Miami Miller School of Medicine, Sylvester Comprehensive Cancer Center.

Related article:
Dietary palmitic acid promotes a metastatic memory via Schwann cells
Gloria Pascual, Diana Domínguez, Carmelo Laudanna, Marc Elosua-Bayes, Claudia Bigas, Felipe Beckedorff, Delphine Douillet, Carolina Greco, Aikaterini Symeonidi, Inmaculada Hernández, Sara Ruiz Gil, Neus Prats, Coro Bescós, Ramin Shiekhattar, Moran Amit, Holger Heyn, Ali Shilatifard & Salvador Aznar Benitah
Nature (2021) DOI: 10.1038/s41586-021-04075-0


About IRB Barcelona

The Institute for Research in Biomedicine (IRB Barcelona) pursues a society free of disease. To this end, it conducts multidisciplinary research of excellence to offer pioneering solutions to unresolved medical needs in cancer and other diseases related to ageing. It establishes technology transfer agreements with the pharmaceutical industry and major hospitals to bring research results closer to society and organises a range of science outreach activities to engage the public in an open dialogue. IRB Barcelona is an international centre that hosts 400 employees and more than 30 nationalities. Recognised as a Severo Ochoa Centre of Excellence since 2011, IRB Barcelona is a CERCA centre and member of the Barcelona Institute of Science and Technology (BIST).